Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 20, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.8K

Evaluating In Vitro DNA Damage Using Comet Assay.

Yanxin Lu1, Yang Liu2, Chunzhang Yang3

  • 1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute; Basic Medical Science Department, Zunyi Medical College-Zhuhai Campus.

Journal of Visualized Experiments : Jove
|October 21, 2017
PubMed
Summary

This study demonstrates the comet assay

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies.

Cancer letters·2026
Same author

Acid Ceramidase Inhibition Disrupts Ceramide Homeostasis and Induces Mitochondrial Apoptosis in IDH1-Mutant Oligodendroglioma.

Research square·2026
Same author

Targeting cell cycle checkpoints for glioma therapy.

Pharmacology & therapeutics·2025
Same author

Cancer Metabolism Meets DNA Repair: The Hidden Link to Therapy Resistance.

BioEssays : news and reviews in molecular, cellular and developmental biology·2025
Same author

Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing.

Cancer letters·2025
Same author

mtKO: A dedicated guide RNA library for mitochondria research.

Proceedings of the National Academy of Sciences of the United States of America·2025

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • DNA damage is a critical cellular event, often induced by cancer therapies like chemotherapy and radiotherapy.
  • Accurate quantification of DNA damage is essential for evaluating the efficacy of genotoxic cancer treatments.
  • The comet assay is a valuable tool for measuring DNA strand breaks in individual cells.

Purpose of the Study:

  • To evaluate the genotoxic effects of the combination therapy of olaparib and temozolomide.
  • To highlight the utility of the comet assay in preclinical cancer research.
  • To quantify DNA damage in U251 glioma cells treated with olaparib/temozolomide.

Main Methods:

  • Utilized the single cell electrophoresis assay, commonly known as the comet assay.

More Related Videos

Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage
11:30

Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage

Published on: March 24, 2020

10.8K
A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage
07:57

A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage

Published on: May 10, 2022

6.1K

Related Experiment Videos

Last Updated: Feb 20, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.8K
Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage
11:30

Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage

Published on: March 24, 2020

10.8K
A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage
07:57

A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage

Published on: May 10, 2022

6.1K
  • Quantified single- and double-strand DNA breaks in vitro.
  • Applied the comet assay to U251 glioma cells for genotoxicity assessment.

    • Main Results:

    • The comet assay effectively quantified DNA damage induced by genotoxic agents.
    • Demonstrated the feasibility of using the comet assay in a preclinical setting.
    • Provided quantitative data on DNA damage from olaparib/temozolomide combination therapy.

    Conclusions:

    • The comet assay is an efficient, reproducible, and cost-effective method for quantifying DNA damage.
    • The study validates the comet assay's utility in assessing the genotoxic impact of combination cancer therapies.
    • Olaparib/temozolomide combination therapy induces significant DNA damage in U251 glioma cells, as measured by the comet assay.